8VYE

SARS-CoV-2 S (C.37 Lambda variant) plus S309, S2L20, and S2X303 Fabs

これはPDB形式変換不可エントリーです。

8VYE の概要

• エントリーDOI: 10.2210/pdb8vye/pdb
• 関連するPDBエントリー: 8VYF 8VYG
• EMDBエントリー: 43658
• 分子名称: Spike glycoprotein, S2L20 Heavy Chain, S2L20 Light Chain, ... (8 entities in total)
• 機能のキーワード: sars-cov-2, coronavirus, lambda, s309, s2l20, s2x303, c.37, antibody, fab, s protein, spike, fusion protein, structural genomics, seattle structural genomics center for infectious disease, ssgcid, viral protein, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2; 詳細
• タンパク質・核酸の鎖数: 21
• 化学式量合計: 662493.98

構造登録者

McCallum, M.,Veesler, D.,Seattle Structural Genomics Center for Infectious Disease (SSGCID) (登録日: 2024-02-08, 公開日: 2024-03-27)

• 主引用文献: Magaret, C.A.,Li, L.,deCamp, A.C.,Rolland, M.,Juraska, M.,Williamson, B.D.,Ludwig, J.,Molitor, C.,Benkeser, D.,Luedtke, A.,Simpkins, B.,Heng, F.,Sun, Y.,Carpp, L.N.,Bai, H.,Dearlove, B.L.,Giorgi, E.E.,Jongeneelen, M.,Brandenburg, B.,McCallum, M.,Bowen, J.E.,Veesler, D.,Sadoff, J.,Gray, G.E.,Roels, S.,Vandebosch, A.,Stieh, D.J.,Le Gars, M.,Vingerhoets, J.,Grinsztejn, B.,Goepfert, P.A.,de Sousa, L.P.,Silva, M.S.T.,Casapia, M.,Losso, M.H.,Little, S.J.,Gaur, A.,Bekker, L.G.,Garrett, N.,Truyers, C.,Van Dromme, I.,Swann, E.,Marovich, M.A.,Follmann, D.,Neuzil, K.M.,Corey, L.,Greninger, A.L.,Roychoudhury, P.,Hyrien, O.,Gilbert, P.B.; Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.; Nat Commun, 15:2175-2175, 2024; PubMed: 38467646; DOI: 10.1038/s41467-024-46536-w

実験手法

ELECTRON MICROSCOPY (2.7 Å)